Healthcare growth, regulated by design

The most common mistake in healthcare growth marketing is the assumption that healthcare is consumer DTC with extra disclosures. The category gets approached with consumer-funnel logic, the team encounters the regulatory frame, the workarounds proliferate, the work softens into something that obeys the law and accomplishes very little else. The category looks hard. The category is not hard. The category is structurally different from consumer DTC, and the marketing organization that does not recognize the difference is operating against the wrong model.

Healthcare growth marketing is its own discipline. It is multi-stakeholder by structure rather than by audience expansion. It is long-cycle by clinical reality rather than by buyer hesitation. It is regulated by design rather than by accident, which is a meaningful distinction we will come back to. The work that compounds in healthcare is the work that operates inside these structural facts as the operating environment, not the obstacle.

This piece sets out the AYMI premise on healthcare. The hub now carries published case studies across providers and payers — UnitedHealth Group, Florida Blue, CVS Health, and Oscar Health. The argument here is the argument those engagements were run against.

Multi-stakeholder is structural

The first structural fact: healthcare is multi-stakeholder by definition. The HCP — the prescribing or referring clinician — sees one set of surfaces and signs off on one set of decisions. The patient sees a different set and makes different decisions. The payer — the insurer, the PBM, the institutional purchaser — sees a third set and gates access to the product entirely.

A growth model that treats one of these stakeholders as the cohort and the others as noise will misallocate spend immediately. The HCP-targeted campaign that converts the HCP cohort but does not consider patient demand or payer access will produce prescriptions that do not get filled. The patient-targeted campaign that builds patient demand but does not consider HCP comfort or payer authorization will produce inquiries that bounce off the access wall. The payer-targeted campaign that satisfies the payer's clinical and economic concerns but does not have HCP advocacy and patient pull will not move policy.

The growth model has to be multi-stakeholder by design. The Method's cadence in healthcare runs three parallel cohort models — HCP, patient, payer — with the attribution model linked at the conversion. The conversion the model anchors on is whichever stakeholder action gates the next step in the buyer's path. For a prescription product, the gating action is most often payer authorization. For a clinical service, it is most often HCP referral. For a self-pay product, it is most often patient activation. The model identifies the gate first, the cadence anchors on it, and the other stakeholder surfaces are calibrated to support it.

Long-cycle by clinical reality

The second structural fact: healthcare conversion cycles are long because the clinical reality is long. The patient who first sees a brand surface for a chronic-condition product is often months from the diagnostic appointment, longer from the prescription, longer still from the first refill. The HCP who is first exposed to clinical evidence is often a year from prescribing the product to a sufficient cohort to register as adoption. The payer policy committee that is first lobbied to add a product to formulary is often two years from a coverage decision.

These are not buyer-hesitation cycles. They are clinical cycles. The marketing model that treats them as buyer-hesitation cycles will under-budget the upper funnel, over-spend the lower funnel, and miss the long-tail conversion.

The model has to follow the clinical cycle. Cohort attribution is at the diagnosis-to-prescription level for patient cohorts, exposure-to-adoption level for HCP cohorts, and policy-cycle level for payer cohorts. CAC, evaluated at month one, will look indefensible. CAC, evaluated at month twelve or twenty-four against the matured cohort, will pay for the program. The discipline is patience, again, communicated in advance to the financial leadership that is reviewing the budget.

Regulated by design

The third structural fact, and the one most often misunderstood: healthcare is regulated by design rather than by accident.

The regulation is not noise. The regulation is the bone structure of how healthcare communication works. The disclosure requirements, the substantiation requirements, the limits on comparative claims, the labeling requirements, the off-label restrictions — these exist because the underlying products carry clinical risk and the buyer is making decisions with their professional license or their physical body. The regulation is doing work the market is asking it to do.

The marketing organization that approaches the regulation as an obstacle will produce work that complies on the surface and erodes trust underneath. The marketing organization that approaches the regulation as the operating environment will produce work that is more credible, more durable, and more effective. The disclosure is not an interruption of the message. The disclosure is part of how the message earns its standing.

In practice, this means the creative testing surface is the disclosure architecture — how the regulated copy is laid out, where it sits in the asset, how it is sequenced relative to the buyer's decision — not the regulated copy itself. It means the brand voice is calibrated to the standing the brand wants to claim, not to the latitude the regulation allows. It means the brand earns trust by being more careful than the regulation requires, not by leaning to the edge of what it permits.

This is the AYMI premise on healthcare communication: regulated by design, not in spite of it.

Editorial-grade clinical content

The creative system that follows is editorial-grade clinical content. The HCP surface needs the rigor of a peer-reviewed publication. The patient surface needs the trust register of a respected health editorial outlet. The payer surface needs the formality of an actuarial brief. The same brand voice carries across all three, and the same modular architecture lets the brand ship variants for each without losing register.

The brands that ship this well treat their content as if it were under peer review even when it is not. The brands that ship this badly treat their content as advertising with disclaimers attached. The buyer can tell the difference, and so can the regulator.

KOL programs and peer-reviewed syndication

The organic surface in healthcare is KOL programs — key opinion leaders, named clinicians whose own credibility is the currency the brand is recruiting — alongside peer-reviewed content syndication and condition-specific community programs. These are slow surfaces. They compound over multi-year horizons. They are also the surfaces that produce durable trust, which is the asset healthcare brands actually compete on.

The brands that build sustained KOL programs over decades are the brands that command HCP preference at the moment of prescription. The brands that approach KOLs as one-off campaign assets do not.

Where AYMI is engaging

AYMI's healthcare practice spans providers and payers, with published case studies on the hub for UnitedHealth Group, Florida Blue, CVS Health, and Oscar Health. The argument those engagements were run against is the argument above: multi-stakeholder by structure, long-cycle by clinical reality, regulated by design.

If you are building inside a regulated healthcare category — provider, payer, pharma, biotech — the conversation starts at the hub.

Building inside healthcare?

Read the healthcare hub →

Start a brief →